Postmarketing Study of Efficacy and Safety of Losartan during the Treatment of Patients with Mild and Moderate Hypertension: LOTHAR Study

被引:2
|
作者
Vasiljevic, Zorana [1 ,2 ]
Dimkovic, Nada [1 ,3 ]
Lazarevic, Katarina [1 ,2 ]
Burmazovic, Snezana [1 ,2 ]
Krstic, Nebojsa [4 ]
Milanovic, Sladjan [5 ]
Zoric, Svetlana [1 ,6 ]
Micic, Dragan [1 ,6 ]
机构
[1] Univ Belgrade, Sch Med, Belgrade, Serbia
[2] Klin Ctr Srbije, Kardiol Klin, Belgrade 11000, Serbia
[3] Zvezdara Med Ctr, Clin Dept Renal Dis & Metab Disorders Dialysis Ct, Belgrade, Serbia
[4] Ctr Clin, Clin Cardiovasc Dis, Nish, Serbia
[5] Univ Belgrade, Inst Med Res, Belgrade, Serbia
[6] Clin Ctr Serbia, Clin Endocrinol Diabet & Metab Dis, Belgrade, Serbia
关键词
arterial hypertension; angiotensin type 1 receptor blocker (ARB); metabolic effects; diabetes mellitus; renal function; BLOOD-PRESSURE; RECEPTOR BLOCKADE; RANDOMIZED TRIAL; RENAL-DISEASE; METAANALYSIS; INHIBITORS; MORTALITY; ATENOLOL; OUTCOMES; EVENTS;
D O I
10.2298/SARH1302022V
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Losartan, the angiotensin type 1 receptor blocker (ARB) exercises its main antihypertensive effect by vasodilatation of peripheral arteries. Objective The aim of this study was to evaluate the antihypertensive effect and safety of losartan in patients with mild and moderate arterial hypertension (AH). Methods This was an open post-marketing study with losartan as monotherapy in previously treated or untreated patients with AH. Primary efficacy parameter was the percentage of patients that achieved target blood pressure after 8-week treatment with a single daily dose of losartan of 50-100 mg. Safety parameters were assessed according to the percentage of adverse events and metabolic effects of therapy. Results The study included 550 patients with AH (59% female and 41% male), mean age 56.8 +/- 11.4 years, BMI = 27 +/- 4 kg/m(2). Losartan was applied in 31% of untreated and 69% of previously treatment-resistant patients After 8 weeks target blood pressure was achieved in 67.8% (SBP) and in 81.1% (DBP) of patients, respectively. The mean decrease was 21.8% for SBP and 21.1% for DBP (p<0.001). Out of all, 65% of patients achieved both target SBP and DBP values. Hydrochlorothiazide was added to the therapy in 11.6% of patients. There were no significant differences in drug efficacy between the entire group and subgroups of patients with diabetes mellitus and impaired renal function (p=ns). Adverse events were rare and metabolic effect was favorable. Conclusion Monotherapy with losartan in a dosage of 50-100 mg applied during 8 weeks resulted in achieving target values of blood pressure in 65% of patient with mild and moderate hypertension, also including the patients with diabetes mellitus and impaired renal function. Losartan is a safe and metabolically neutral medication.
引用
收藏
页码:22 / 28
页数:7
相关论文
共 50 条
  • [1] Postmarkethig Study of Efficacy and Safety of Losartan during the Treatment of Patients with Mild and Moderate Hypertension: LOTHAR Study (vol 141, pg 22, 2013)
    Vasiljevic, Z.
    Dimkovic, N.
    Lazarevic, K.
    Burmazovic, S.
    Krstic, N.
    Milanovic, S.
    Zoric, S.
    Micic, D.
    [J]. SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2013, 141 (3-4) : 282 - 282
  • [2] A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension
    Fernández-Vega F.
    Abellan J.
    Sanz De Castro S.
    Cucalón J.M.
    Maceira B.
    Gómez De La Cámara A.
    [J]. International Urology and Nephrology, 2001, 32 (4) : 519 - 523
  • [3] Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension - A pilot study
    Desai, AA
    Samra, SS
    Gawde, AS
    Baliga, VP
    Jain, MM
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 86A - 87A
  • [4] The safety and efficacy of losartan/hydrochlorothiazide in the treatment of patients with severe hypertension; A multicenter study
    Aurup, P
    Smith, RD
    Snavely, D
    Oparil, S
    [J]. JOURNAL OF HYPERTENSION, 2000, 18 : S99 - S99
  • [5] A MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF AMLODIPINE IN MILD-TO-MODERATE HYPERTENSION
    CROSS, BW
    KIRBY, MG
    MILLER, S
    SHAH, SH
    SHELDON, DM
    SWEENEY, MT
    [J]. BRITISH JOURNAL OF CLINICAL PRACTICE, 1993, 47 (05): : 237 - 240
  • [6] Clinical efficacy and safety of irbesartan in patients with mild and moderate hypertension. Results of a multicenter study
    Belousov, YB
    [J]. KARDIOLOGIYA, 2000, 40 (07) : 4 - 8
  • [7] A COMPARATIVE-STUDY OF THE EFFICACY AND SAFETY OF QUINAPRIL AND LISINOPRIL IN PATIENTS WITH MILD-TO-MODERATE HYPERTENSION
    PAPAGEORGIOU, A
    KARAYIANNIS, A
    ATHYROS, V
    DOUMA, S
    PETIDIS, K
    ZAMBOULIS, C
    [J]. DRUG INVESTIGATION, 1994, 7 (01): : 13 - 17
  • [8] An open label study to investigate the safety and efficacy of 12 weeks treatment with telmisartan in patients with mild-moderate hypertension
    Farsang, C
    Ingino, C
    Karpov, Y
    Laucevicius, A
    Mabayoje, MO
    O'Shaughnessy, D
    Dawson, M
    [J]. JOURNAL OF HYPERTENSION, 2003, 21 : S319 - S319
  • [9] SAFETY AND EFFICACY OF LISINOPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE HYPERTENSION
    MARLIER, R
    VANDEPAPELIERE, P
    DEVRIESE, G
    [J]. JOURNAL OF HUMAN HYPERTENSION, 1989, 3 : 163 - 167
  • [10] Efficacy and Safety of Olmesartan in the Treatment of Mild-to-Moderate Essential Hypertension in Chinese Patients
    Chiau-Suong Liau
    Chii-Ming Lee
    Sheng-Hsiung Sheu
    Kwo-Chang Ueng
    Kuo-Liong Chien
    Ta-Chen Su
    Wen-Ter Lai
    Ming-Cheng Lin
    Cheng-Sheng Lin
    Chung-Sheng Lin
    [J]. Clinical Drug Investigation, 2005, 25 : 473 - 479